Last reviewed · How we verify

5-Hydroxytryptophan

Elizabeth Berry-Kravis · FDA-approved active Small molecule

5-Hydroxytryptophan (5-HTP) is a precursor to serotonin that increases central nervous system serotonin levels by crossing the blood-brain barrier and being converted to serotonin via aromatic amino acid decarboxylase.

5-Hydroxytryptophan (5-HTP) is a precursor to serotonin that increases central nervous system serotonin levels by crossing the blood-brain barrier and being converted to serotonin via aromatic amino acid decarboxylase. Used for Depression (off-label use), Insomnia (off-label use), Fibromyalgia (off-label use).

At a glance

Generic name5-Hydroxytryptophan
Also known as5-HTP, Basic Vitamins, 5HTP
SponsorElizabeth Berry-Kravis
Drug classSerotonin precursor / amino acid supplement
TargetAromatic amino acid decarboxylase (enzyme substrate); indirect serotonin system modulation
ModalitySmall molecule
Therapeutic areaPsychiatry / Neurology / Sleep Medicine
PhaseFDA-approved

Mechanism of action

5-HTP is an amino acid intermediate in the serotonin synthesis pathway. After oral administration, it crosses the blood-brain barrier more efficiently than serotonin itself and is converted to serotonin by the enzyme aromatic amino acid decarboxylase. This increases synaptic serotonin availability, which modulates mood, sleep, and other serotonin-dependent functions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: